Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany), Dr Friederike Schlurmann (Centre Hospitalier Universitaire de Brest, Brest, France), Dr Elena Castro (Spanish National Cancer Research Center, Madrid, Spain) and Prof Gerhardt Attard (University College London: Cancer Institute, London, UK) discuss the use of PARPi combinations to treat patients with mCRPC.

Dr Schlurmann discusses the current landscape for PARP inhibitors in mCRPC. Dr Castro explores the potential use of PARP inhibitors in prostate cancer and their application in an mHSPC setting.

Prof Attard delves into testing and advises healthcare professionals on the PARP inhibitor combination therapies relevant to the mCRPC landscape.

The panel also reviews studies such as TALAPRO-2, ZZFIRST, MAGNITUDE, and a study investigating fuzuloparib for mCRPC.